CRM
Salesforce, Inc.
CRM has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
CRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
CRM's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 20x | $218 | — |
| Cheap | 36x | $393 | +80% |
| Fair | 70x | $766 | +252% |
| Expensive | 293x | $3,206 | +1374% |
Historical ranges are pointers, not guarantees.
CRM has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CRM Forward outlook
There aren't enough analyst estimates for CRM to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $10.96 | +59% |
| Q2 2026 | $8.63 | +35% |
| Q1 2026 | $7.80 | +23% |
| Q4 2025 | $7.49 | +23% |
| Q3 2025 | $6.88 | +20% |
| Q2 2025 | $6.39 | +15% |
| Q1 2025 | $6.36 | +51% |
| Q4 2024 | $6.08 | +131% |
CRM has the edge over NVO on earnings, with stronger typical year-over-year growth.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
CRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3B | +11% |
| Q2 2026 | $11.1B | +13% |
| Q1 2026 | $11.2B | +12% |
| Q4 2025 | $10.3B | +8.6% |
| Q3 2025 | $10.2B | +9.8% |
| Q2 2025 | $9.8B | +7.6% |
| Q1 2025 | $10B | +7.6% |
| Q4 2024 | $9.4B | +8.3% |
CRM's revenue has grown year over year every quarter since late 2020: $11.3B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -2.2 points |
| Q2 2026 | 21% | +1.3 points |
| Q1 2026 | 17% | -1.5 points |
| Q4 2025 | 21% | +1.3 points |
| Q3 2025 | 23% | +3.7 points |
| Q2 2025 | 20% | +1.1 points |
| Q1 2025 | 18% | +0.7 points |
| Q4 2024 | 20% | +2.8 points |
CRM's operating margin was 21% last quarter, down 2.2 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CRM on profitability, with a higher operating margin.
CRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +81% |
| Q2 2026 | $6.6B | +4.1% |
| Q1 2026 | $5.3B | +39% |
| Q4 2025 | $2.2B | +22% |
| Q3 2025 | $605M | -20% |
| Q2 2025 | $6.3B | +3.5% |
| Q1 2025 | $3.8B | +17% |
| Q4 2024 | $1.8B | +30% |
CRM has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.7% | -50M shares |
| 1 year | -15% | -141M shares |
| 3 years | -17% | -165M shares |
| 5 years | -14% | -129M shares |
| Available history | -6.6% | -58M shares |
CRM has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $84M |
| Q2 2026 | $27.2B |
| Q1 2026 | $3.9B |
| Q4 2025 | $3.8B |
| Q3 2025 | $2.2B |
| Q2 2025 | $2.6B |
| Q1 2025 | $76M |
| Q4 2024 | $1.3B |
CRM spent $35.1B buying back its own shares over the past year, about six times what it spent the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 0.0x | Very low |
CRM's net debt is about 2.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over CRM on leverage, with a lower net debt burden relative to earnings.
CRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 44.2 | Neutral |
CRM's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRM PE vs Technology Sector
| Metric | CRM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 29% below |
| PE % | 2 | 35 | 33 pts below |
CRM is trading at 20x earnings, a 29% discount to the Technology sector's median of 28x, though its recent earnings include one-off gains.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over CRM on valuation relative to its sector.
CRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $230.9 | 5.8% below |
| 20 week MA | $214.7 | 1.3% above |
| 50 week MA | $206.8 | 5.2% above |
| 100 week MA | $239.7 | 9.2% below |
| 200 week MA | $242.0 | 10% below |
CRM has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $165.0 | $225.8 | +37% |
| 2021 | $225.8 | $253.1 | +12% |
| 2022 | $253.1 | $129.4 | -49% |
| 2023 | $129.4 | $263.1 | +103% |
| 2024 | $263.1 | $338.5 | +29% |
| 2025 | $338.5 | $266.1 | -21% |
| 2026 YTD | $266.1 | $217.6 | -18% |
CRM has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.